NO323517B1 - ICE-inhiberende peptider og farmasoytiske sammensetninger omfattende slike, samt anvendelse av peptidene for fremstilling av medikament. - Google Patents
ICE-inhiberende peptider og farmasoytiske sammensetninger omfattende slike, samt anvendelse av peptidene for fremstilling av medikament. Download PDFInfo
- Publication number
- NO323517B1 NO323517B1 NO19992079A NO992079A NO323517B1 NO 323517 B1 NO323517 B1 NO 323517B1 NO 19992079 A NO19992079 A NO 19992079A NO 992079 A NO992079 A NO 992079A NO 323517 B1 NO323517 B1 NO 323517B1
- Authority
- NO
- Norway
- Prior art keywords
- ice
- peptide
- pil
- lane
- seq
- Prior art date
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims description 44
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 239000003814 drug Substances 0.000 title claims description 4
- 229940079593 drug Drugs 0.000 title claims description 3
- 102000004196 processed proteins & peptides Human genes 0.000 title description 15
- 238000002360 preparation method Methods 0.000 title description 3
- 230000002401 inhibitory effect Effects 0.000 title 1
- 102000004190 Enzymes Human genes 0.000 claims description 17
- 108090000790 Enzymes Proteins 0.000 claims description 17
- 150000001413 amino acids Chemical class 0.000 claims description 11
- 230000007170 pathology Effects 0.000 claims description 5
- 208000023275 Autoimmune disease Diseases 0.000 claims description 4
- 230000001580 bacterial effect Effects 0.000 claims description 4
- 238000004519 manufacturing process Methods 0.000 claims description 4
- 208000030507 AIDS Diseases 0.000 claims description 3
- 208000035143 Bacterial infection Diseases 0.000 claims description 3
- 208000036142 Viral infection Diseases 0.000 claims description 3
- 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
- 208000027866 inflammatory disease Diseases 0.000 claims description 3
- 231100000518 lethal Toxicity 0.000 claims description 3
- 230000001665 lethal effect Effects 0.000 claims description 3
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 3
- 206010039073 rheumatoid arthritis Diseases 0.000 claims description 3
- 230000009385 viral infection Effects 0.000 claims description 3
- 206010000890 Acute myelomonocytic leukaemia Diseases 0.000 claims description 2
- 206010009900 Colitis ulcerative Diseases 0.000 claims description 2
- 208000033835 Myelomonocytic Acute Leukemia Diseases 0.000 claims description 2
- 206010040070 Septic Shock Diseases 0.000 claims description 2
- 201000006704 Ulcerative Colitis Diseases 0.000 claims description 2
- 208000011912 acute myelomonocytic leukemia M4 Diseases 0.000 claims description 2
- 210000004899 c-terminal region Anatomy 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 201000006417 multiple sclerosis Diseases 0.000 claims description 2
- 230000036303 septic shock Effects 0.000 claims description 2
- 238000011282 treatment Methods 0.000 claims description 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 5
- 230000008105 immune reaction Effects 0.000 claims 1
- 108010002352 Interleukin-1 Proteins 0.000 description 21
- 102000000589 Interleukin-1 Human genes 0.000 description 21
- 210000004027 cell Anatomy 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 17
- 230000000694 effects Effects 0.000 description 14
- 101150055276 ced-3 gene Proteins 0.000 description 13
- 102000004169 proteins and genes Human genes 0.000 description 13
- 108091005804 Peptidases Proteins 0.000 description 12
- 108010005636 polypeptide C Proteins 0.000 description 12
- 239000002243 precursor Substances 0.000 description 12
- 235000018102 proteins Nutrition 0.000 description 12
- 102000035195 Peptidases Human genes 0.000 description 11
- 239000004365 Protease Substances 0.000 description 11
- 230000005764 inhibitory process Effects 0.000 description 11
- 210000001616 monocyte Anatomy 0.000 description 10
- 101800005149 Peptide B Proteins 0.000 description 9
- 102100029855 Caspase-3 Human genes 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 235000001014 amino acid Nutrition 0.000 description 7
- 239000002299 complementary DNA Substances 0.000 description 7
- 108010091748 peptide A Proteins 0.000 description 7
- 108090000397 Caspase 3 Proteins 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 108020004999 messenger RNA Proteins 0.000 description 5
- 102000004091 Caspase-8 Human genes 0.000 description 4
- 108090000538 Caspase-8 Proteins 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 101710188315 Protein X Proteins 0.000 description 4
- 230000001640 apoptogenic effect Effects 0.000 description 4
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000030833 cell death Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000034994 death Effects 0.000 description 4
- 210000002950 fibroblast Anatomy 0.000 description 4
- 230000003834 intracellular effect Effects 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108010005843 Cysteine Proteases Proteins 0.000 description 3
- 102000005927 Cysteine Proteases Human genes 0.000 description 3
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 3
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 3
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 239000006166 lysate Substances 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- 108090000567 Caspase 7 Proteins 0.000 description 2
- 102100025597 Caspase-4 Human genes 0.000 description 2
- 102100038902 Caspase-7 Human genes 0.000 description 2
- 101000828805 Cowpox virus (strain Brighton Red) Serine proteinase inhibitor 2 Proteins 0.000 description 2
- 229920001917 Ficoll Polymers 0.000 description 2
- 101000715398 Homo sapiens Caspase-1 Proteins 0.000 description 2
- 101000933112 Homo sapiens Caspase-4 Proteins 0.000 description 2
- 101001076407 Homo sapiens Interleukin-1 receptor antagonist protein Proteins 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 239000012980 RPMI-1640 medium Substances 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 235000003704 aspartic acid Nutrition 0.000 description 2
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- 230000006882 induction of apoptosis Effects 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- 230000004983 pleiotropic effect Effects 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 229940044551 receptor antagonist Drugs 0.000 description 2
- 239000002464 receptor antagonist Substances 0.000 description 2
- 238000003757 reverse transcription PCR Methods 0.000 description 2
- 230000011664 signaling Effects 0.000 description 2
- PWJFNRJRHXWEPT-UHFFFAOYSA-N ADP ribose Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OCC(O)C(O)C(O)C=O)C(O)C1O PWJFNRJRHXWEPT-UHFFFAOYSA-N 0.000 description 1
- SRNWOUGRCWSEMX-KEOHHSTQSA-N ADP-beta-D-ribose Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H]1O)O)N1C=2N=CN=C(C=2N=C1)N)OP(O)(=O)OP(O)(=O)OC[C@H]1O[C@@H](O)[C@H](O)[C@@H]1O SRNWOUGRCWSEMX-KEOHHSTQSA-N 0.000 description 1
- 241000024188 Andala Species 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 241000244203 Caenorhabditis elegans Species 0.000 description 1
- 102100026548 Caspase-8 Human genes 0.000 description 1
- 102000004039 Caspase-9 Human genes 0.000 description 1
- 108090000566 Caspase-9 Proteins 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000001398 Granzyme Human genes 0.000 description 1
- 108060005986 Granzyme Proteins 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 101000983528 Homo sapiens Caspase-8 Proteins 0.000 description 1
- 101000611023 Homo sapiens Tumor necrosis factor receptor superfamily member 6 Proteins 0.000 description 1
- 101001074035 Homo sapiens Zinc finger protein GLI2 Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 229940119178 Interleukin 1 receptor antagonist Drugs 0.000 description 1
- 102000051628 Interleukin-1 receptor antagonist Human genes 0.000 description 1
- 108090000978 Interleukin-4 Proteins 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 101100059157 Mus musculus Casp2 gene Proteins 0.000 description 1
- 208000000112 Myalgia Diseases 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 108020005067 RNA Splice Sites Proteins 0.000 description 1
- 101710146873 Receptor-binding protein Proteins 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 108060008683 Tumor Necrosis Factor Receptor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 102100040403 Tumor necrosis factor receptor superfamily member 6 Human genes 0.000 description 1
- 102100035558 Zinc finger protein GLI2 Human genes 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000001270 agonistic effect Effects 0.000 description 1
- 238000003277 amino acid sequence analysis Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 230000008485 antagonism Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 230000009925 apoptotic mechanism Effects 0.000 description 1
- 230000001363 autoimmune Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 230000009931 harmful effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 102000046824 human IL1RN Human genes 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 description 1
- 102000009634 interleukin-1 receptor antagonist activity proteins Human genes 0.000 description 1
- 108040001669 interleukin-1 receptor antagonist activity proteins Proteins 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 210000002864 mononuclear phagocyte Anatomy 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000000861 pro-apoptotic effect Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000001698 pyrogenic effect Effects 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 108010001130 tetrapeptide B Proteins 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 102000003298 tumor necrosis factor receptor Human genes 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Zoology (AREA)
- Heart & Thoracic Surgery (AREA)
- Toxicology (AREA)
- Transplantation (AREA)
- Virology (AREA)
- Hematology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP1996/004738 WO1998018823A1 (en) | 1996-10-31 | 1996-10-31 | Ice inhibiting peptides |
Publications (3)
Publication Number | Publication Date |
---|---|
NO992079D0 NO992079D0 (no) | 1999-04-29 |
NO992079L NO992079L (no) | 1999-06-16 |
NO323517B1 true NO323517B1 (no) | 2007-06-04 |
Family
ID=8166387
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO19992079A NO323517B1 (no) | 1996-10-31 | 1999-04-29 | ICE-inhiberende peptider og farmasoytiske sammensetninger omfattende slike, samt anvendelse av peptidene for fremstilling av medikament. |
Country Status (20)
Country | Link |
---|---|
US (1) | US6380162B1 (ru) |
EP (1) | EP0938500B1 (ru) |
JP (1) | JP4018154B2 (ru) |
KR (1) | KR100502211B1 (ru) |
AR (1) | AR011269A1 (ru) |
AT (1) | ATE277079T1 (ru) |
BR (1) | BR9612755A (ru) |
CA (1) | CA2269638C (ru) |
DE (1) | DE69633463T2 (ru) |
DK (1) | DK0938500T3 (ru) |
EA (1) | EA001866B1 (ru) |
EE (1) | EE04782B1 (ru) |
ES (1) | ES2225893T3 (ru) |
IL (1) | IL129669A0 (ru) |
NO (1) | NO323517B1 (ru) |
PT (1) | PT938500E (ru) |
SI (1) | SI0938500T1 (ru) |
UA (1) | UA70291C2 (ru) |
WO (1) | WO1998018823A1 (ru) |
ZA (1) | ZA979712B (ru) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI1899378T1 (sl) * | 2005-06-21 | 2010-02-26 | Xoma Technology Ltd | IL-1Beta vezavna protitelesa in njihovi fragmenti |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5981713A (en) * | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
IT1270662B (it) | 1994-10-13 | 1997-05-07 | Applied Research Systems | Antagonista della interleuchina-1 |
-
1996
- 1996-10-31 PT PT96937313T patent/PT938500E/pt unknown
- 1996-10-31 EA EA199900432A patent/EA001866B1/ru not_active IP Right Cessation
- 1996-10-31 SI SI9630696T patent/SI0938500T1/xx unknown
- 1996-10-31 AT AT96937313T patent/ATE277079T1/de not_active IP Right Cessation
- 1996-10-31 US US09/297,369 patent/US6380162B1/en not_active Expired - Fee Related
- 1996-10-31 IL IL12966996A patent/IL129669A0/xx unknown
- 1996-10-31 UA UA99052981A patent/UA70291C2/uk unknown
- 1996-10-31 WO PCT/EP1996/004738 patent/WO1998018823A1/en active IP Right Grant
- 1996-10-31 DE DE69633463T patent/DE69633463T2/de not_active Expired - Fee Related
- 1996-10-31 DK DK96937313T patent/DK0938500T3/da active
- 1996-10-31 JP JP51995298A patent/JP4018154B2/ja not_active Expired - Fee Related
- 1996-10-31 BR BR9612755-4A patent/BR9612755A/pt not_active Application Discontinuation
- 1996-10-31 ES ES96937313T patent/ES2225893T3/es not_active Expired - Lifetime
- 1996-10-31 CA CA002269638A patent/CA2269638C/en not_active Expired - Fee Related
- 1996-10-31 KR KR10-1999-7003693A patent/KR100502211B1/ko not_active IP Right Cessation
- 1996-10-31 EE EEP199900178A patent/EE04782B1/xx not_active IP Right Cessation
- 1996-10-31 EP EP96937313A patent/EP0938500B1/en not_active Expired - Lifetime
-
1997
- 1997-10-29 ZA ZA979712A patent/ZA979712B/xx unknown
- 1997-10-29 AR ARP970105024A patent/AR011269A1/es active IP Right Grant
-
1999
- 1999-04-29 NO NO19992079A patent/NO323517B1/no not_active IP Right Cessation
Also Published As
Publication number | Publication date |
---|---|
WO1998018823A8 (en) | 1999-06-17 |
CA2269638A1 (en) | 1998-05-07 |
BR9612755A (pt) | 1999-10-19 |
ES2225893T3 (es) | 2005-03-16 |
EP0938500A1 (en) | 1999-09-01 |
NO992079D0 (no) | 1999-04-29 |
DE69633463T2 (de) | 2006-02-23 |
KR20000052858A (ko) | 2000-08-25 |
EP0938500B1 (en) | 2004-09-22 |
EA001866B1 (ru) | 2001-10-22 |
DK0938500T3 (da) | 2005-01-17 |
AU729946B2 (en) | 2001-02-15 |
ATE277079T1 (de) | 2004-10-15 |
JP4018154B2 (ja) | 2007-12-05 |
DE69633463D1 (de) | 2004-10-28 |
AR011269A1 (es) | 2000-08-16 |
EA199900432A1 (ru) | 1999-10-28 |
IL129669A0 (en) | 2000-02-29 |
ZA979712B (en) | 1999-02-05 |
PT938500E (pt) | 2005-02-28 |
EE9900178A (et) | 1999-12-15 |
US6380162B1 (en) | 2002-04-30 |
AU2702399A (en) | 1999-08-16 |
NO992079L (no) | 1999-06-16 |
WO1998018823A1 (en) | 1998-05-07 |
SI0938500T1 (en) | 2005-02-28 |
KR100502211B1 (ko) | 2005-07-19 |
EE04782B1 (et) | 2007-02-15 |
CA2269638C (en) | 2005-01-18 |
UA70291C2 (en) | 2004-10-15 |
JP2001510452A (ja) | 2001-07-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Dinarello | Interleukin-1, interleukin-1 receptors and interleukin-1 receptor antagonist | |
Stennicke et al. | Caspases–controlling intracellular signals by protease zymogen activation | |
Tanaka et al. | Downregulation of Fas ligand by shedding | |
US7799901B2 (en) | Modulators of the function of FAS receptors and other proteins | |
Kwak et al. | Intracellular interleukin (IL)-1 family cytokine processing enzyme | |
Berke | The Fas-based mechanism of lymphocytotoxicity | |
Wallach et al. | Exploring cell death mechanisms by analyzing signaling cascades of the TNF/NGF receptor family | |
AU747005B2 (en) | Modulators of the function of receptors of the TNF/NGF receptor family | |
NO323517B1 (no) | ICE-inhiberende peptider og farmasoytiske sammensetninger omfattende slike, samt anvendelse av peptidene for fremstilling av medikament. | |
NO327854B1 (no) | DNA-sekvens, replikerbar ekspresjonsvektor, transformert eukaryot eller prokaryot vertscelle; RAP-2 protein, isoform, fragment, funksjonell analog eller derivater derav samt fremgangsmate for fremstilling og anvendelse derav; farmasoytisk preparat, anvendelse av en rekombinant dyrevirusvektor og en vektor kodende for ribozym sekvens. | |
AU740223B2 (en) | CASH (Caspase Homologue) with death effector domain, modulators of the function of FAS receptors | |
AU729946C (en) | Ice inhibiting peptides | |
US20030035789A1 (en) | Compositions and methods for caspase-induced apoptosis | |
MXPA99004046A (en) | Ice inhibiting peptides | |
JP2002541120A (ja) | 血液細胞の増殖阻害用及び自動免疫疾患の治療用カスパーゼ阻害剤 | |
US20020034813A1 (en) | Novel protease FMH-1 | |
Feldmann et al. | Pathogenesis of Rheumatoid Arthritis? | |
Rose-John et al. | Interleukin-6 receptor | |
KR20220164450A (ko) | Agkistrodon piscivorus piscivorus 또는 Naja melanoleuca로부터 유래된 신규한 펩타이드, 및 이를 포함하는 베체트병 또는 류마티스 관절염의 치료용 조성물 | |
JPH10271998A (ja) | ポリペプチドの製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
CREP | Change of representative |
Representative=s name: ONSAGERS AS, POSTBOKS 6963 ST OLAVS PLASS, 0130 OS |
|
CREP | Change of representative |
Representative=s name: ZACCO NORWAY AS, POSTBOKS 2003 VIKA, 0125 OSLO, NO |
|
MM1K | Lapsed by not paying the annual fees |